email article
Intravenous immune globulin (IVIG) helped resolve the effects of vaccine-induced thrombotic thrombocytopenia (VITT) in three patients following receipt of the AstraZeneca COVID-19 vaccine, a case series in Canada found.
Following administration of high-dose IVIG, all three patients with VITT experienced reduced antibody-induced platelet activation, reported Ishac Nazy, PhD, of McMaster University in Hamilton, Ontario, and colleagues.
All patients had arterial thrombotic events, and two also had venous thrombosis. However, no patients had evidence of new or progressive thrombosis following IVIG treatment, they wrote in a brief report in the
The authors noted that VITT mimics autoimmune heparin-induced thrombocytopenia, and high-dose IVIG helps reduce platelet activation. They added that because minimal data exist for treating patients with VITT, they used an analogy with autoimmune heparin-induced thrombocytopenia, where immune globulin rapidly increases th
A Canadian research team has published new evidence highlighting a combination of two treatments that could help patients suffering from a rare, but potentially-deadly, post-vaccine blood clot condition.
Can AstraZeneca be tweaked so that it doesn t lead to blood clots?
Vaxx Populi: Researchers are getting faster at recognizing, diagnosing and treating VITT, and there is hope that they re zeroing in on what causes it
June 3, 2021 A man arrives at a COVID-19 vaccination clinic in Montreal, on Tuesday, June 1, 2021. THE CANADIAN PRESS/Paul Chiasson
As Ontario, Nova Scotia and other provinces distribute second doses of the AstraZeneca vaccine to residents, there is good news about the troubled COVID-19 vaccine. Not only are doctors and researchers around the world getting faster at recognizing, diagnosing and treating the rare blood clotting syndrome that can occur after a shot of the vaccine, but there is now hope that scientists are zeroing in on what causes vaccine-induced immune thrombotic thrombocytopenia (VITT). The syndrome, which can occur between four and 28 days after vaccination, features both blood clots and low platelet counts. And it’s those tiny blood cells, which
Read more about AstraZeneca vax 2nd dose FAQs about blood clots, safety, risks and symptoms on Business Standard. Rare but serious blood clots that have been linked the AstraZeneca Covid-19 vaccine have many people especially those who have already had one dose of the vaccine looking for information
updated: Jun 01 2021, 14:39 ist
By Dawn ME Bowdish and Ishac Nazy for The Conversation
Rare but serious blood clots that have been linked to the AstraZeneca Covid-19 vaccine (marketed as Covishield in India) have many people especially those who have already had one dose of the vaccine looking for information. Here are answers to some key questions.
If I had a first dose of the AstraZeneca Covid-19 vaccine, should I have concerns about safety?
As long as there is a risk, you should always be aware and informed. A risk of very serious harm, including death, does exist, though it is very small: about one in 55,000 for the first dose.